Nu Skin Enterprises, Inc 8-K, filed Jun 2, 2022
Nu Skin Enterprises, Inc. (NUS)
8-K
2022-06-02
For: 2022-05-27
View Original
Added on
April 08, 2026
About this 8-K
Nu Skin Enterprises, Inc filed this 8-K on June 2, 2022, reporting on events of May 27, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
|
|
Date of Report (Date of earliest event reported)
|
|
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
||
|
(Address of principal executive offices and zip code)
|
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
|
N/A
|
||
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Effective May 31, 2022, Connie Tang, the Executive Vice President and Chief Global Growth and Customer Experience Officer of Nu Skin
Enterprises, Inc. (the “Company” or “we”), began a temporary medical leave of absence to undergo a medical procedure that requires a few months of focused recovery. Ms. Tang notified the Company of her decision to take this leave on May 27, 2022.
Ryan Napierski, the Company’s President and CEO, will lead Ms. Tang’s organization while she recovers during the next approximately three months. We wish her a speedy recovery and look forward to her return.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NU SKIN ENTERPRISES, INC.
|
||
|
(Registrant)
|
||
|
/s/ Mark H. Lawrence
|
||
|
Mark H. Lawrence
|
||
|
Chief Financial Officer
|
||
|
Date: June 2, 2022
|
||